[1] Roitt L, Brostoff J, Male D. Immunology[M]. Harcourt Asia Pte Ltd USA, 2001. 236.
[2] Reynolds J EF Martindale. The Extra Pharmacopoeia [M]. 32th ed. Loudon: Royal pharmaceutical society publication department UK, 1999. 615-622.
[3] Rudick RA, Ransohoff RM. Biologic effects of interferons: relevance to multiple sclerosis [J]. Mult Scler, 1995, 1 (Suppl 1): S12-16.
[4] Shuai K, Schindler C, Prezioso VR, et al. Activation of transcription by IFN-gamma: tyrosine phosphorylation of a 91-Kd DNA binding protein [J]. Science, 1992, 258: 1808-1812.
[5] de Veer MJ, Holko M, Frevel M, et al. Functional classification of interferon-stimulated genes identified using microarrays [J]. J Leukocyte Biol, 2001, 69: 912-920.
[6] Hovnanian A, Rebouillat D, Mattei MG, et al. The human 2’,5’-oligoadenylate synthetase locus is composed of three distinct genes clustered on chromosome 12q24. 2 encoding the 100-, 69-, and 40-kDa forms [J]. Genomics, 1998, 52: 267-277.
[7] Ruvolo V, Navarro L, Sample CE, et al. The Epstein-Barr virus SM protein induces STAT1 and interferon-stimulated gene expression [J]. J Virol, 2003, 77: 3690-3701.
[8] Ji X, Cheung R, Cooper S, et al. Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C [J]. Hepatology, 2003, 37: 610-621.
[9] Younossi ZM, Mullen KD, Hodnick S, et al. Triple combination of interferon alfa-2b, ribavirin, and amantadine for treatment of chronic hepatitis C [J]. J Clin Gastroenterol, 2003, 36: 427-430.
[10] Sreenarasimhaiah J, Jaramillo A, Crippin J, et al. Concomitant augmentation of type 1 CD4 (+) and CD8 (+) T-cell responses during successful interferon-alfa and ribavirin treatment for chronic hepatitis C virus infection [J]. Hum Immunol, 2003, 64: 497-504.
[11] Keating GM, Curran MP. Peg-interferon-alfa-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C [J]. Drugs, 2003, 63: 701-730.
[12] Jessner W, Stauber R, Hackl F, et al. Early viral kinetics on treatment with pegylated interferon-alfa-2a in chronic hepatitis C virus genotype 1 infection [J]. J Viral Hepat, 2003, 10: 37-42.
[13] Neri S, Pistone G, Saraceno B, et al. L-Carnitine decreases severity and type of fatigue induced by interferon-alfa in the treatment of patients with hepatitis C [J]. Neuropsychobiology, 2003, 47: 94-97.
[14] Portales P, Reynes J, Pinet V, et al. Interferon-alfa restores HIV-induced alteration of natural killer cell perforin expression in vivo [J]. AIDS, 2003, 17: 495-504.
[15] Chin YE, Kitagawa M, Kuida K, et al. Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis [J]. Mol Cell Biol, 1997, 17: 5328-5337.
[16] Cinatl J, Morgenstern B, Bauer G, et al. Treatment of SARS with human interferons [J]. Lancet, 2003, 362 (9380): 293-294. |
>
>